Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging

Ball State University

Status: Completed

Conditions: Aging; Endothelial Dysfunction; Cardiovascular Function; Arterial Stiffness

Treatments: Dietary Supplement: Placebo; Dietary Supplement: Mitoquinone Mesylate

Study type: Interventional

Funder types: Other

Identifiers

NCT05872139

MitoQ

Details and patient eligibility

About

The primary goal of this intervention is to determine the efficacy of acute mitochondrial-specific antioxidants to improve vascular endothelial function in middle-aged and older (≥45 y) adults who do no perform regular aerobic exercise. In a double-blind, randomized, placebo-controlled crossover design participants with receive both MitoQ and placebo arm of the study. Primary endpoints will include vascular endothelial function assessed by brachial artery flow-mediated dilation and cardiac function assessed via pulse wave analysis. Secondary endpoints will include measures of aortic stiffness assessed by carotid-femoral pulse wave velocity and carotid artery stiffness (e.g. β-stiffness) and elasticity (carotid compliance, distensibility, and Youngs elastic modulus) from ultrasonography.

Enrollment: 23 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Resting brachial blood pressure <160 mmHg (systolic)/<100 mmHg (diastolic)
• Body mass index ≤ 35 kg/m2
• Nonsmoker
• Women must be postmenopausal defined as cessation of menses ≥ 1 year.

Exclusion criteria

• cardiovascular/metabolic medications
• known clinical disease
• absolute contraindications to exercise testing

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

23 participants in 2 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

Gelatin capsules

Treatment:

Dietary Supplement: Placebo

MitoQ

Experimental group

Description:

Capsules containing mitoquinone mesylate (MitoQ, 5 mg/capsule) totaling 80 mg were taken once.

Treatment:

Dietary Supplement: Mitoquinone Mesylate